StockData
Ligand Pharmaceuticals Inc logo

Ligand Pharmaceuticals Inc (LGND) stock

LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)

Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –

Earnings

Ligand Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$78.70M
-31.9% on a year earlier
Adjusted earnings per diluted share, Q3 FY2026
$2.67
$3.09 a year earlier
Latest guidance
Lowered
Oct 29, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of Ligand Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026before the open$78.70M-31.9%-$1.43$2.67Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$63.70M+33.8%$2.22$2.37Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$51.70M+14.1%-$0.67$1.63Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$59.70M+39.5%$2.12–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$115.50M+123.0%$5.68$3.09Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$47.60M+14.7%$0.24$1.60Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$45.30M+46.1%-$2.21$1.33Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$42.80M+52.3%-$1.64$1.27Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$51.80M+57.4%-$0.39$1.84Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024after the close$41.50M+57.2%-$2.88$1.40Release
Q1 FY2024ended Mar 31, 2024May 7, 2024after the close$31.00M-29.5%$4.75$3.84Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Ligand Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
royalty revenueFY2026$225.00M – $250.00M$10.00M – $20.00MLoweredAug 6, 2026
Total revenueFY2026$270.00M – $310.00M–NewOct 29, 2026
Adjusted earnings per diluted sharenon-GAAPFY2026$9.50 – $9.75–NewOct 29, 2026
Adjusted earnings per diluted sharenon-GAAPFY2026$9.00 – $9.50$8.50 – $9.50RaisedAug 6, 2026
Adjusted Net Incomenon-GAAPFY2026$195.00M – $206.00M–NewAug 6, 2026
Captisol salesFY2026$35.00M – $40.00M–LoweredOct 29, 2026
Contract revenueFY2026$10.00M – $20.00M–LoweredOct 29, 2026
GAAP Net IncomeGAAPFY2026$107.00M – $118.00M–NewAug 6, 2026
Royalty revenueFY2026$225.00M – $250.00M–NewOct 29, 2026

Guidance vs results

The last range Ligand Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$225.00M – $235.00M$268.10MΣ4QAbove range

Guidance history

Every forecast Ligand Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026Adjusted earnings per diluted shareFY2026$9.50 – $9.75New
Oct 29, 2026Royalty revenueFY2026$225.00M – $250.00MNew
Oct 29, 2026Captisol salesFY2026$35.00M – $40.00MLowered
Oct 29, 2026Contract revenueFY2026$10.00M – $20.00MLowered
Oct 29, 2026Total revenueFY2026$270.00M – $310.00MNew
Aug 6, 2026Adjusted earnings per diluted shareFY2026$9.00 – $9.50Raised
Aug 6, 2026Adjusted Net IncomeFY2026$195.00M – $206.00MNew
Aug 6, 2026GAAP Net IncomeFY2026$107.00M – $118.00MNew
Aug 6, 2026royalty revenueFY2026$225.00M – $250.00MLowered
Aug 6, 2026Contract revenueFY2026$10.00M – $20.00MLowered
Aug 6, 2026Total revenueFY2026$270.00M – $310.00MRaised
Aug 6, 2026Revenue from sales of CaptisolFY2026$35.00M – $40.00MLowered
May 7, 2026adjusted earnings per diluted shareFY2026$8.50 – $9.50Raised
May 7, 2026contract revenueFY2026$10.00M – $20.00MLowered
May 7, 2026royalty revenueFY2026$225.00M – $250.00MLowered
May 7, 2026total revenueFY2026$270.00M – $310.00MRaised
May 7, 2026Revenue from sales of CaptisolFY2026$35.00M – $40.00MLowered
Feb 26, 2026adjusted earnings per diluted shareFY2026$8.00 – $9.00New
Feb 26, 2026contract revenueFY2026$10.00M – $20.00MLowered
Feb 26, 2026total revenueFY2026$245.00M – $285.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Ligand Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Update
  6. News
  7. News
  8. News
  9. Results
  10. News
  11. News
  12. Results
  13. Results
  14. News
  15. News

See a number that looks wrong?